Skip to content
DataLookout
Menu

NCT07497503

A Study of B-3E07 and Forsteo® in Healthy Adult Female Participants

StatusCompleted
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 8 words Show 5 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Sep 30, 2026 to Oct 7, 2026
    • Study completion date changed from estimate of Oct 14, 2026 to Oct 21, 2026
    • Secondary endpoints: details revised at 5 of 12 entries
    • Site details revised
  2. Minor Primary completion pushed from Jun 10, 2026 to Sep 30, 2026
    • Study completion pushed from Jun 24, 2026 to Oct 14, 2026
    v3
  3. Notable Recruitment openedv2 Show 6 more changesShow less
    • Primary endpoint(s) modified
    • Eligibility criteria expanded, about 8 words
    • Primary completion date: May 29, 2026 to Jun 10, 2026
    • Study completion date: Jun 11, 2026 to Jun 24, 2026
    • Secondary endpoints: details revised at 4 of 12 entries
    • Site details revised
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Maximum Plasma Concentration (Cmax) of B-3E07
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC 0-inf) of B-3E07
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
Cmax of Forsteo®
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose
AUC 0-inf of Forsteo®
Timeframe: Treatment Periods 1 and 2: Day 1 - Pre-dose and up to 6 hours post-dose

Secondary (12)

Area Under the Plasma Concentration-time Curve up to Time t (AUC 0-t) of B-3E07 and Forsteo®
Time to Attain Maximal Plasma Concentration (Tmax) of B-3E07 and Forsteo®
Terminal Elimination Half-life (t1/2) of B-3E07 and Forsteo®
Volume of Distribution (Vz/F) of B-3E07 and Forsteo®
Apparent Clearance (CL/F) of B-3E07 and Forsteo®
Show 7 moreShow less
Maximum Observed Effect (Emax) of B-3E07 and Forsteo®
Area Under the Effect-time Curve to the Last Measurable Time Point (AUEC 0-t) of B-3E07 and Forsteo®
Time to Attain Maximal Serum Concentration (Tmax) of B-3E07 and Forsteo®
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Number of Participants With Injection Site Reactions
Number of Participants With Clinically Significant Changes in Vital Signs, 12-lead Electrocardiograph (ECG), Physical Examinations, and Laboratory Test Results
Percentage of Participants With Positive Antidrug antibodies (ADA) and ADA Titers to B-3E07 and Forsteo®

Arms and interventions

Sequence 1: B-3E07 Followed by Forsteo ®Experimental

Participants will receive the B-3E07 as a single subcutaneous (SC) injection on Day 1 of Period 1 followed by the Forsteo® on Day 1 of Period 2. There will be a 14-day washout between each dosing (Day 1 of each period) and a follow-up of 14-days after the last dose.

Sequence 2: Forsteo® Followed by B-3E07Active comparator

Participants will receive the Forsteo® as a single SC injection on Day 1 of Period 1 followed by the B-3E07 on Day 1 of Period 2. There will be a 14-day washout between each dosing (Day 1 of each period) and a follow-up of 14-day after the last dose.

Biologicals: Forsteo®, B-3E07

Sites

1 site in 1 country

  • Veritus ResearchBayswater, Victoria, Australia